XML 138 R94.htm IDEA: XBRL DOCUMENT v3.22.4
Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)
€ in Millions, $ in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Jul. 01, 2015
agreement
Jul. 31, 2022
EUR (€)
Jul. 31, 2022
USD ($)
Jun. 30, 2022
EUR (€)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Dec. 31, 2015
USD ($)
Disclosure of Principal Alliances [Line Items]                      
Other operating income/(expenses), net related to the Regeneron Alliance | €             € (1,231)   € (1,373) € (926)  
Assets held for sale or exchange | €             85   € 89 € 83 [1]  
Regeneron Pharmaceuticals, INC                      
Disclosure of Principal Alliances [Line Items]                      
Assets held for sale or exchange | €             226        
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement                      
Disclosure of Principal Alliances [Line Items]                      
Number of agreements signed | agreement   2                  
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)                     10.00%
Percentage of cumulative development costs reimbursed                     50.00%
Upfront payments for projects under collaboration agreements | $               $ 900      
Regular milestone payments for projects under collaboration agreements         € 96 $ 100   $ 100      
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement                      
Disclosure of Principal Alliances [Line Items]                      
Upfront payments for projects under collaboration agreements     € 856 $ 900              
Royalty income percentage (percentage)     11.00% 11.00%              
Other operating income/(expenses), net related to the Regeneron Alliance | €             111        
Proceeds from collaboration agreements | €             € 967        
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Development of cemiplimab (REGN2810)                      
Disclosure of Principal Alliances [Line Items]                      
Prior development budget in total | $                     $ 1,640
Contractual agreement for anti-programmed cell death protein                     5000.00%
Maximum additional funding for PD1 - part of each company | $ $ 1,840                   $ 820
PD1 sales milestone payment from Sanofi | $                     375
Minimum sales of PD1 in 12-month period to be achieved for milestone payment | $                     $ 2,000
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.